IN THE CLAIMS:

Please **cancel** claims 3, 15, 19-21 and 25 without prejudice.

Please **amend** the claims as follows:

1. (Twice Amended) A pharmaceutical preparation for the application of antiseptic agents or agents which promote the healing of wounds to the lower respiratory tract, comprising aerosolized or nebulized inhalable particulate carriers suitable for administration into the lower respiratory tract combined with an agent selected from the group consisting of an antiseptic agent, a wound-healing agent or a combination thereof.

4. (Twice Amended) The preparation of claim 1, wherein the antiseptic agent is selected from the group consisting of oxygen- releasing compounds, halogen-releasing compounds, metal compounds, organic disinfectants, alcohols, phenols, quinolines, acridines, hexahydropyrimidines, quaternary ammonium compounds, iminium salts, guanidines and combinations thereof.

5. (Twice Amended) The preparation according to claim 4, wherein the antiseptic agent is selected from the group consisting of metal compounds, phenol, phenol derivatives, iodine, iodine complexes and combinations thereof.

7. (Twice Amended) The preparation according to claim 1, wherein the wound-healing promoting agent is selected from the group consisting of dexpanthenol, allantoines, azulenes, tannines, vitamin B compounds and combinations thereof.

9. (Twice Amended) The preparation of claim 1, wherein the carrier particles have a size in the range of between 1 and about 50 μm.

10. (Twice Amended) The preparation of claim 1, wherein the carrier particles have a size in the range of between 20 and about 30 μm.

16. (Twice Amended) The preparation of claim 1, wherein, the aerosolized or nebulized carrier particles are derived from a compacted solid medicament reservoir, a ring-tablet, a gelatin capsule, a powder, a spray, an emulsion, a suspension or a solution containing the carrier and agent or agents in a pharmaceutically acceptable solid or liquid formulation, which is suitable for the generation of inhalable particles.

17. (Twice Amended) The preparation of claim 1, wherein said particulate carrier comprises:

(a) liposomes comprising a pharmaceutically acceptable liposome membrane forming substance; and

(b) a 0.1 to 2% PVP iodine solution, wherein the liposomes are in a size between about 1μm and about 50μm.

18. (Twice amended) The preparation according to claim 17, wherein the liposomes are in a size range between 20μm and 30μm diameter for application to the trachea.

22. (Twice Amended) A method of treating infections of the lower respiratory tract in a human or animal comprising administering a pharmaceutical preparation to the lower respiratory tract, said preparation comprising an inhalable particulate carrier combined with an agent selected from the group consisting of an antiseptic agent, a wound-healing agent or a combination thereof.

23. (Twice Amended) A method of providing functional tissue remodeling and repair in the lower respiratory tract in a human or animal comprising administering a pharmaceutical preparation to the lower respiratory tract comprising an inhalable

particulate carrier combined with an agent selected from the group consisting of an antiseptic agent, a wound-healing agent or a combination thereof.

24. (~~Twice~~ Amended) The method of claim 22 or 23, wherein said particulate carrier is selected from the group consisting of a liposome preparation, a microsphere preparation, a nanoparticle preparation, a Large Porous Particle preparation a laser-pulse polymer coated molecule preparation and a combination thereof.

27. (Twice Amended) The method of claim 22 or 23, wherein the antiseptic agent is selected from the group consisting of oxygen- releasing compounds, halogen-releasing compounds, metal compounds, organic disinfectants, alcohols, phenols, quinolines, acridines, hexahydropyrimidines, quaternary ammonium compounds , iminium salts, guanidines and a combination thereof.

28. (Twice Amended) The method of claim 22 or 23, wherein the antiseptic agent is selected from the group consisting of metal compounds, phenol, phenol derivatives, iodine, iodine complexes and a combination thereof.

30. (~~Twice~~ Amended) The method of claim 22 or 23, wherein the wound-healing promoting agent is selected from the group consisting of dexpanthenol, allantoines, azulenes, tannines, vitamin B compounds and a combination thereof.

32. (Twice Amended) The method of claim 22 or 23, wherein the carrier particles have a size in the range between about 1 μm and about 50 μm.

33. (Twice Amended) The method according to claim 32, wherein the carrier particles have a size in the range between 20 μm and 30 μm diameter for application to the trachea.

38. (Twice Amended) The method of claim 22 or 23, wherein the particulate carrier is suitable for administration via nebulization or aerolsolization.

40. (Amended) The method of claim 22 or 23, wherein said particulate carrier comprises:

(a) liposomes comprising a pharmaceutically acceptable liposome membrane forming substance; and

(b) a 0.1 to 2% PVP iodine solution, wherein the liposomes are in a size between about 1μm and about 50μm.

41. (Twice Amended) The method of claim 22 or 23, wherein the liposomes are in a size range between 20 μm and 30 μm diameter for application to the trachea.

44. (Amended) The preparation according to claim 9, wherein the carrier particles have a size in the range between 1μm to about 30μm.

45. (Amended) The preparation according to claim 10, wherein the carrier particles have a size in the range between about 10μm and 20μm diameter for application to the bronchi.

46. (Amended) The preparation according to claim 10, wherein the carrier particles have a size in the range between 1μm and 6μm diameter for application to the alveoli.

47. (Amended) The preparation according to claim 10, wherein the carrier particles have a size in the range between 2μm and 5μm diameter for application to the alveoli.

48. (Amended) The preparation according to claim 17, wherein the liposomes have a size in the range of 10μm and 20μm diameter for application to the bronchi.

49. (Amended) The preparation according to claim 17, wherein the liposomes have a size in the range of 1μm and 6μm diameter for application to the alveoli.

50. (Amended) The preparation according to claim 17, wherein the liposomes a size in the range of 2μm and 5μm diameter for application to the alveoli.

51. (Amended) The method of claim 22 or 23, wherein the carrier particles have a size in the range between about 1μm and about 30μm.

52. (Amended) The method according to claim 32, wherein the carrier particles have a size in the range between 10μm and 20μm diameter for application to the bronchi.

53. (Amended) The method according to claim 32, wherein the carrier particles size in the range between 1μm and 6μm diameter for application to the alveoli.

54. (Amended) The method according to claim 32, wherein the carrier particles have a size in the range between 2μm and 5μm diameter for application to the alveoli.

55. (Amended) The method of claim 22 or 23, wherein the liposomes have a size in the range between 10μm and 20μm diameter for application to the bronchi.

56. (Amended) The method of claim 55, wherein the liposomes have a size in the range between 1μm and 6μm diameter for application to the alveoli.

57. (Amended) The method of claim 56, wherein the liposomes have a size in the range between 2μm and 5μm diameter for application to the alveoli.